Compare CVS Health Corp (CVS) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs L3Harris Technologies Inc — how do they compare? CVS Health Corp trades at $94.88 (market cap $119.58B), while L3Harris Technologies Inc trades at $288.11 (market cap $53.26B). The key difference: CVS Health Corp is far larger — about 2.2× L3Harris Technologies Inc's market cap, and CVS Health Corp pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| CVS | LHX | |
|---|---|---|
Market Cap | $119.58B | $53.26B |
Sector | Health | Industrials |
52-Week High | $110.60 | $378.48 |
52-Week Low | $65.51 | $270.21 |
Enterprise Value | $181.93B | $63.71B |
Dividend Yield | 2.84% | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.
CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.
LHX trades at $285.18, down 1.57% today, with strong fundamental performance including three consecutive quarterly EPS beats and record $42 billion backlog. The company shows improving profitability with net margin expanding to 8.11% in 2026 projections. Recent defense contract wins and successful missile tests highlight operational momentum, though technical indicators show bearish pressure with price below key resistance levels.
LHX presents a compelling investment case with strong defense sector positioning, consistent earnings outperformance, and 72.7% analyst buy ratings targeting $319.33. Key risks include defense budget volatility and execution challenges in scaling production. The stock offers 12% upside to consensus target with dividend yield support, though near-term technical weakness requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
